Marie-Eve Robinson

Phase 2b, Randomized, Double-Blind, Placebo Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children with Achondroplasia

Feasibility and acceptability of a virtual self-compassion intervention for parents and caregivers of children with chronic conditions: The Self-Care First Aid (SCFA) study.

Brittle Bone Disorders Consortium of the Rare Disease Clinical Research Network

QED Therapeutics A Phase 2/3, Multicenter, Open-Label Phase followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children with Hypochondroplasia: ACCEL 2/3

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children with Achondroplasia: PROPEL OLE